Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2016

01-08-2016

Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients

Authors: Martin A. Bishop, Michael B. Streiff

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2016

Login to get access

Abstract

Anticoagulation (AC) clinics use the percentage of time in the therapeutic INR range (%TTR) to characterize the quality of management for patients treated with warfarin. In order to guide policy and procedure changes, the purpose of this quality improvement (QI) study was to characterize the AC patient population at The Johns Hopkins Hospital (JHH). We set out to investigate the impact of AC clinic provider continuity on the quality of anticoagulation management. This QI study is a retrospective chart review of 525 warfarin patients managed by pharmacists in the Hematology AC Management Clinic at JHH from June 28, 2013 to November 1, 2014. We recorded patient demographic and clinical characteristics and the quality of AC management using %TTR, and compared these parameters between patients with (Group A) and without a primary AC (Group B). Group A patients had a significantly higher %TTR than Group B patients (53.2 vs. 46.5 %, p = 0.008). In conclusion, we found that patients with a primary AC clinic provider had a higher %TTR than patients with multiple providers. If confirmed prospectively, this approach to warfarin management could represent one technique for AC clinics to optimize patient management and clinical outcomes.
Literature
1.
go back to reference Ageno W, Gallus AS, Wittkowsky A, Crowthe M, Hylek E, Palareti G (2012) American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88SCrossRefPubMedPubMedCentral Ageno W, Gallus AS, Wittkowsky A, Crowthe M, Hylek E, Palareti G (2012) American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88SCrossRefPubMedPubMedCentral
2.
go back to reference Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129:837–847CrossRefPubMed Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129:837–847CrossRefPubMed
4.
go back to reference Rieder MJ, Reiner AP, Gage BF, Nickerson DA, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293CrossRefPubMed Rieder MJ, Reiner AP, Gage BF, Nickerson DA, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293CrossRefPubMed
5.
go back to reference Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661–1665CrossRefPubMed Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661–1665CrossRefPubMed
6.
go back to reference Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson KA, Bass EB (2000) Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 15:56–67CrossRefPubMedPubMedCentral Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson KA, Bass EB (2000) Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 15:56–67CrossRefPubMedPubMedCentral
7.
go back to reference Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106CrossRefPubMed Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106CrossRefPubMed
8.
go back to reference Self TH, Reaves AB, Oliphant CS, Sands C (2006) Does heart failure exacerbation increased response to warfarin? A critical review of the literature. Curr Med Res Opin 22(11):2089–2094CrossRefPubMed Self TH, Reaves AB, Oliphant CS, Sands C (2006) Does heart failure exacerbation increased response to warfarin? A critical review of the literature. Curr Med Res Opin 22(11):2089–2094CrossRefPubMed
9.
go back to reference Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell’Era A, Sei C, Mannucci PM (2007) The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 46:520–527CrossRefPubMed Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell’Era A, Sei C, Mannucci PM (2007) The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 46:520–527CrossRefPubMed
10.
go back to reference Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 118:511–520CrossRefPubMed Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 118:511–520CrossRefPubMed
11.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239PubMed Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239PubMed
12.
go back to reference Samsa GP, Matchar DB (2000) Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trial of patient self-management. J Thromb Thrombolysis 9:283–292CrossRefPubMed Samsa GP, Matchar DB (2000) Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trial of patient self-management. J Thromb Thrombolysis 9:283–292CrossRefPubMed
13.
go back to reference van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155–1166CrossRefPubMed van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155–1166CrossRefPubMed
14.
go back to reference Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR (2003) Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 169:293–298PubMedPubMedCentral Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR (2003) Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 169:293–298PubMedPubMedCentral
15.
go back to reference Wilt VM, Gums JG, Ahmed OI, Moore LM (1995) Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 15:732–739PubMed Wilt VM, Gums JG, Ahmed OI, Moore LM (1995) Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 15:732–739PubMed
16.
go back to reference Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158:1641–1647CrossRefPubMed Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158:1641–1647CrossRefPubMed
17.
go back to reference Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127:1515–1522CrossRefPubMed Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127:1515–1522CrossRefPubMed
18.
go back to reference Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM (2009) Warfarin dose management affects INR control. J Thromb Haemost 7:94–101CrossRefPubMed Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM (2009) Warfarin dose management affects INR control. J Thromb Haemost 7:94–101CrossRefPubMed
19.
go back to reference Lind M, Fahlén M, Kosiborod M, Eliasson B, Odén A (2012) Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 129:32–35CrossRefPubMed Lind M, Fahlén M, Kosiborod M, Eliasson B, Odén A (2012) Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 129:32–35CrossRefPubMed
20.
go back to reference Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Kaatz S, Eikelboom JW (2010) Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in a therapeutic range: a pilot study. J Thromb Haemost 8(1):101–106CrossRefPubMed Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Kaatz S, Eikelboom JW (2010) Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in a therapeutic range: a pilot study. J Thromb Haemost 8(1):101–106CrossRefPubMed
21.
go back to reference Nieuwlaat R, Hubers LM, Spyropoulos AC, Eikelboom JW, Connolly BJ, Van Spall HCG, Schulze KM, Cuddy SM, Stehouwer AC, Schulman S, Connolly SJ (2012) Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. J Thromb Haemost 108(6):1228–1235CrossRef Nieuwlaat R, Hubers LM, Spyropoulos AC, Eikelboom JW, Connolly BJ, Van Spall HCG, Schulze KM, Cuddy SM, Stehouwer AC, Schulman S, Connolly SJ (2012) Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. J Thromb Haemost 108(6):1228–1235CrossRef
22.
go back to reference Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, COAG Investigators (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283–2293CrossRefPubMedPubMedCentral Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, COAG Investigators (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283–2293CrossRefPubMedPubMedCentral
23.
go back to reference Sawicki PT (1999) A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 281:145–150CrossRefPubMed Sawicki PT (1999) A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 281:145–150CrossRefPubMed
24.
go back to reference Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B (2000) A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 83:661–665PubMed Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B (2000) A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 83:661–665PubMed
25.
go back to reference van Walraven C, Oake N, Jennings A, Forster AJ (2010) The association between continuity of care and outcomes: a systematic and critical review. J Eval Clin Pract 16(5):947–956CrossRefPubMed van Walraven C, Oake N, Jennings A, Forster AJ (2010) The association between continuity of care and outcomes: a systematic and critical review. J Eval Clin Pract 16(5):947–956CrossRefPubMed
Metadata
Title
Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients
Authors
Martin A. Bishop
Michael B. Streiff
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1359-y

Other articles of this Issue 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.